Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00434239
Other study ID # 06/49
Secondary ID
Status Active, not recruiting
Phase Phase 0
First received February 11, 2007
Last updated January 8, 2013
Start date February 2007
Est. completion date May 2014

Study information

Verified date January 2013
Source Peter MacCallum Cancer Centre, Australia
Contact n/a
Is FDA regulated No
Health authority Australia: Department of Health and Ageing Therapeutic Goods Administration
Study type Interventional

Clinical Trial Summary

This study is mainly assessing the safety of Revlimid in combination with Ancestim (recombinant human stem cell factor) in patients with symptomatic myelodysplasia. Of those two compounds, Revlimid has been shown to be an active drug in myelodysplasia. Clinical responses will also be assessed.


Description:

Aim: The primary objective is to assess the safety of Revlimid in combination with Ancestim in patients with symptomatic myelodysplasia. The secondary objectives are: Duration of response and assessment of changes in gene expression profile of bone marrow samples from patients undergoing such treatment.

Potential Significance: Myelodysplastic syndromes (MDS) are malignant hematopoietic stem cell disorders. Prognosis can be estimated by use of the International Prognostic Scoring System (IPSS) which divides patients into low, intermediate-1, intermediate-2, and high-risk groups with corresponding median survival times of 5.7 years, 3.5 years, 1.2 years, and 0.4 years, respectively. There is currently no standard treatment for MDS and management is often purely symptomatic with transfusion of blood products and antibiotic treatment of infections.

A recent phase II study however has shown significant response rates with Revlimid as a single agent in patients with MDS. The total response rate was 56%. The effects of Revlimid and SCF on hematopoietic progenitors cells were examined in vitro. RhSCF and Revlimid were shown to be synergistic in stimulating the proliferation of hematopoietic progenitor cells and their precursors in vitro, thereby forming the rationale for this study.

Research Plan: This is a single-centre, open label, single-arm, non-comparative study, in which 25 patients will be enrolled. The study will include patients who meet all the inclusion and none of the exclusion criteria, as per the respective protocol section.

The patients will be enrolled sequentially to receive 2 different dose levels of Ancestim with a fixed dose of Revlimid. This will determine the feasibility and tolerability of the combination of Revlimid and Ancestim. Patients will start with an 8 week course of single agent Revlimid as 10mg daily oral treatment day 1-21 in a 28 day cycle. If patients do not achieve a complete remission on single agent Revlimid they will start on Ancestim s.c. injections. Two dose levels of Ancestim (10 and 20 mcg/kg s.c. daily for 7 days) will be evaluated.

Safety: Safety will be assessed by the reporting of adverse events (starting with the first study-related procedure, during treatment, and for a period of 60 days following discontinuation of treatment). The intensity of the adverse events will be assessed using National Cancer Institute common toxicity criteria. All adverse events will be recorded on the case report forms (CRFs). Furthermore, assessments of physical (including neurological / peripheral neurological) examinations, vital signs measurements, and haematology and clinical chemistry tests will be used to monitor safety. Clinically relevant changes in laboratory safety tests, vital signs, and physical examinations will be recorded as adverse events. The adverse event sections of the CRFs will be submitted to a representative of the sponsor at the end of each treatment cycle. Serious adverse events will be reported as they occur, on forms provided by the sponsor.

Efficacy: Response to treatment will be assessed according to the guidelines of the international working group to standardize response criteria for myelodysplastic syndromes. This will be done on bone marrow biopsies (including cytogenetic analyses) and peripheral blood counts. An additional scientific investigation will examine gene-expression profiles of bone-marrow and blood samples at different time points and will try to correlate those with response to treatment. Concomitant in-vitro studies will assess surrogate markers of response.

Statistical Methods: Adverse events, serious adverse events, transfusion requirements, response data and Karnofsky performance status data will be summarized.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 25
Est. completion date May 2014
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Understand and voluntarily sign an informed consent form.

2. Age >18 years at the time of signing the informed consent form.

3. Able to adhere to the study visit schedule and other protocol requirements.

4. Patients must have a confirmed myelodysplastic syndrome regardless of subgroup according to the WHO classification and their prognostic group. Patients with treatment associated MDS are allowed on this study, however the number is restricted to 10 (50% of patients anticipated to receive combination treatment). Patients with CMML are eligible but restricted in number to up to 3 in total.

5. The patients must have either:

1. symptomatic anemia as defined as Hb < 10g/dl OR

2. transfusion-dependent anaemia as defined as requiring more than 4 units of packed red blood cells over 8 weeks

6. All previous cancer therapy, including erythropoietin, thalidomide and other experimental therapies must have been discontinued at least 4 weeks prior to treatment in this study.

Exclusion Criteria:

1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.

2. Pregnant or lactating females.

3. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

4. Use of any other experimental drug or therapy within 28 days of baseline.

5. Known hypersensitivity to thalidomide.

6. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.

7. Any prior use of Revlimid or SCF.

8. Concurrent use of other anti-cancer agents or treatments including erythropoietin.

9. Known positive for HIV or infectious hepatitis, type B or C.

10. Mast cell diseases (systemic mastocytosis, urticaria pigmentosa or diffuse cutaneous mastocytosis)

11. History of severe anaphylaxis, asthma, recurrent urticaria, recurrent angiooedema

12. Known hypersensitivity against to Escherichia coli derived products.

13. Prior chemotherapy or stem cell transplantation for the treatment of myelodysplasia.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Lenalidomide + Ancestim
Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle

Locations

Country Name City State
Australia Peter MacCallum Cancer Centre East Melbourne Victoria

Sponsors (2)

Lead Sponsor Collaborator
Peter MacCallum Cancer Centre, Australia Celgene Corporation

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity as defined by NCI-CTCv3.0 3 years Yes
Secondary Response 3 years No
Secondary Pharmacodynamics defined in protocol No
Secondary Change in Biomarkers defined in protocol No
See also
  Status Clinical Trial Phase
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00606437 - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants Phase 1
Recruiting NCT02323867 - Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies Phase 2
Completed NCT01933035 - Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. N/A
Completed NCT00990587 - Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy Phase 1
Terminated NCT00594308 - In-Vivo Activated T-Cell Depletion to Prevent GVHD N/A
Terminated NCT00514722 - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies N/A
Completed NCT00513175 - Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia N/A
Recruiting NCT04202835 - ATG Plus PTCy vs ATG for CGVHD Prophylaxis Phase 2
Completed NCT03613727 - Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients Phase 2
Completed NCT00580242 - A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia Phase 1
Completed NCT00506402 - A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies Phase 1
Completed NCT00516152 - Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT Phase 2
Completed NCT01956799 - Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy
Terminated NCT00109538 - Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) Phase 3
Completed NCT00578942 - Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath Phase 2
Active, not recruiting NCT00145626 - HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Phase 2
Active, not recruiting NCT00899223 - Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes
Recruiting NCT04800458 - Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis N/A
Recruiting NCT05735717 - MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies Phase 2